BRAF and metastatic melanoma: Dabrafenib was an inhibitor of BRAF kinase, which could be used solely to treat unresectable or metastatic melanoma with BRAF V600E mutation, and to treat BRAF V600E or V600K mutated melanoma combined with trametinib (96).